Crescendo Launches First Dx in Test Suite to Improve Care of Rheumatoid Arthritis Patients | GenomeWeb

This article has been corrected to note that Vectra DA doesn't diagnose rheumatoid arthritis but assesses patients' disease activity.

By Turna Ray

Crescendo Bioscience
last week announced the commercial launch of Vectra DA, a multi-biomarker blood test that aims to help doctors manage rheumatoid arthritis patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.